FORMULATION AND EVALUATION OF TRAMADOL HYDROCHLORIDE SUSTAINED RELEASE TABLETS
Article Sidebar
Main Article Content
Abstract
The objective of the present study was to formulate sustained-release matrix tablets of Tramadol hydrochloride, for treatment of pain. The matrix tablets were prepared by direct compression method using hydroxyl propyl methylcellulose K4M, Carbopol 934 in various concentrations. The powder showed satisfactory flow properties and compressibility. All the formulations showed acceptable pharmacopoeial standards. Successful formulation was found stable after evaluation for physicochemical parameters when kept for 90 days at room temperature, 400c and 2-8 0 c. It concluded that sustained release matrix tablets of Tramadol hydrochloride containing of HPMC K4M and Carbopol 934 provide a better option for Sustained release of drug.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
LeonL Lachmann, Theory and Practice of Industrial Pharmacy, 3rd Edition, Varghese Publishing House: 430-456.
M. Dhasmana, w. rating and b. Lachmann, 1990, therapeutic application of Tramadol in the treatment of pain compared to other opiates Indian journal of pharmacology 22: 184-191.
Reddy KR, Srinivas Mutalik and Srinivas Reddy, 2003. Preparation of once-daily sustained release matrix tablets of nicorandil. AAPS Pharm sci tech; 4(4), 61.
Kulkarni G.T, Gowthamarajan K, Suresh B. stability testing of pharmaceutical product: an overview. Indian J Phar Edu. 2004, 38(4): p.no.194-202
Kanvide S A, Kulkarni M S, Stability of oral solid dosage form: A global perspective. Pharma Time 2005,37(5): p.no. 9-15
Mohrle R. Effervescent tablets in Liberman HA, Lachman L, editor. Pharmaceutical dosage form –Tablet, Marcel Dekker Inc, New York:1980, p.no. -232-246(vol-1)
Khan G.M., Zhu J.B, “Studies on drug release kinetics from ibuprofun carbomer hydrophilic matrix tablets” J. Cont. Rel.,1999, 57, p.no.197-203.
Hoyashi T, Kanbe H, Okado M. Suzuki M, Sonobe T. “formulation study and drug release mechanism of a new theophylline Sustained Release preparation” Int. J. Pharm, 2005,304, p.no. 91-101.
Solinis M.A, Cruz Y. De, Gascon A, Calvo B, Pedraz J. L “Release of Ketoprofen enantiomeres from HPMC K100M matrices –Diffusion studies” Int. J. Pharm., 2002,239, p.no. 61-68.
Qiu Y. Chidambaram N, Porter W. Flood K., “Formulation and characterization of new diffusional matrices for Zero – order sustained release” J. Cont. Rel., 1998,52, p.no.149-158.
Chambers HF. General Considerations of antimicrobial therapy. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill Medical Publishing Division; 2006. pp. 969–73.
Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999; 13:27–36.
Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40:52–62.